Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q33554907)
Watch
English
Combination therapy for osteoporosis: a reappraisal
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
24795812
retrieved
28 July 2017
title
Combination therapy for osteoporosis: a reappraisal
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
24795812
retrieved
28 July 2017
main subject
osteoporosis
0 references
author name string
Felicia Cosman
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
24795812
retrieved
28 July 2017
publication date
2 April 2014
1 reference
stated in
Europe PubMed Central
PubMed ID
24795812
retrieved
28 July 2017
published in
BoneKEy reports
1 reference
stated in
Europe PubMed Central
PubMed ID
24795812
retrieved
28 July 2017
volume
3
1 reference
stated in
Europe PubMed Central
PubMed ID
24795812
retrieved
28 July 2017
page(s)
518
1 reference
stated in
Europe PubMed Central
PubMed ID
24795812
retrieved
28 July 2017
exact match
https://scigraph.springernature.com/pub.10.1038/bonekey.2014.13
0 references
cites work
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
21 June 2018
Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
21 June 2018
Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
21 June 2018
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
21 June 2018
Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
21 June 2018
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
21 June 2018
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
21 June 2018
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
21 June 2018
Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
31 October 2018
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
31 October 2018
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
31 October 2018
Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
31 October 2018
Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
31 October 2018
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
31 October 2018
Daily and cyclic parathyroid hormone in women receiving alendronate
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
31 October 2018
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
31 October 2018
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
31 October 2018
The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
31 October 2018
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
31 October 2018
Impact of marrow fat on accuracy of quantitative CT.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007166
retrieved
31 October 2018
Combination therapy with risedronate and teriparatide in male osteoporosis
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24795812
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Accuracy and the influence of marrow fat on quantitative CT and dual-energy X-ray absorptiometry measurements of the femoral neck in vitro
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24795812
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24795812
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24795812
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1038/BONEKEY.2014.13
1 reference
stated in
Europe PubMed Central
PubMed ID
24795812
retrieved
28 July 2017
Dimensions Publication ID
1000199499
0 references
PMCID
4007166
1 reference
stated in
Europe PubMed Central
PubMed ID
24795812
retrieved
28 July 2017
PubMed ID
24795812
1 reference
stated in
Europe PubMed Central
PubMed ID
24795812
retrieved
28 July 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
